Progesterone receptor: stability studies and correlation between steroid binding assay and enzyme immunoassay.

1988 ◽  
Vol 34 (10) ◽  
pp. 1987-1991 ◽  
Author(s):  
J T Wu ◽  
L W Wilson
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Enzyme Immunoassay ◽  
Binding Assay ◽  
Progesterone Receptors ◽  
Stability Studies ◽  
Analytical Recovery ◽  
Steroid Binding ◽  
The Stability

Abstract We evaluated and compared Abbott Laboratories' newly developed enzyme immunoassay (EIA) for measuring progesterone receptors (PgR) with that of DuPont's steroid-binding assay (SBA). We also used both methods to study the stability of PgR under various conditions. THere were excellent correlations for all 59 cytosols compared (r = 0.94) and for the 44 cytosols containing PgR greater than 10 fmol per milligram of protein (r = 0.93), but the correlation for cytosols containing less than 10 fmol of PgR per milligram was poor. We found PgR to be more stable as assayed by EIA than by SBA. The biological half-lives of PgR at 30, 4, and -60 degrees C were approximately 3 h, 6 days, and 19 days, respectively. The effect of molybdate on PgR is complex. Its presence during tissue homogenization leads to analytical recovery of more PgR and may stabilize PgR during storage. Its presence during enzyme immunoassay is less critical. Unlike estrogen receptor, PgR is not protected by its ligand, R5020.

Breast cancers negative for estrogen receptor but positive for progesterone receptor, a true entity?

1987 ◽  
Vol 5 (4) ◽  
pp. 662-666 ◽  
Author(s):  
D T Kiang ◽  
R Kollander
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Staining Method ◽  
Binding Assay ◽  
Assay Method ◽  
Breast Cancers ◽  
Antibody Method ◽  
Steroid Binding ◽  
Rare Group ◽  
Er Status

By the conventional steroid-binding assay method for receptor, 3% of 1,095 primary breast cancers (or 10.6% of 263 premenopausal tumors) were classified as negative for estrogen receptor (ER), but positive for progesterone receptor (PR). The true ER status in this rare group of tumors was further investigated by the enzyme-immunoassay (EIA) or immunocytochemical (ICA) staining method using monoclonal antibodies H222 and D547. Immunoreactive ER was present in nine ER-/PR+ tumors studied, whereas it was not detectable in nine age-matched ER-/PR- tumors. Immunoreactive ER was also present in 24 ER+ breast cancers studied, and was particularly higher in tumors that were PR+. Measurement of immunoreactive ER by monoclonal antibody method provides certain advantages over the conventional dextran-coated charcoal (DCC) method, especially in ER-/PR+ tumors.

An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa

1995 ◽  
Vol 5 (4) ◽  
pp. 275-281 ◽  
Author(s):  
H. Kerner ◽  
E. Sabo ◽  
M. Friedman ◽  
D. Beck ◽  
O. Samare ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Endometrial Cancer ◽  
Progesterone Receptor ◽  
Estrogen Receptor Status ◽  
Endometrial Adenocarcinoma ◽  
Progesterone Receptors ◽  
Myometrial Invasion ◽  
Inverse Correlation ◽  
Immunohistochemical Analysis ◽  
Receptor Status

The immunoperoxidase stain for estrogen and progesterone receptor content in endometrial adenocarcinoma was correlated with the grade and stage, level of myometrial invasion, age and survival of the patients. Anti-estrogen and anti-progesteone receptor monoclonal antibodies were applied to paraffin-embedded tissue from hysterectomy specimens of 100 patients with adenocarcinoma of the endometrium. In 34 of the cases the receptors were studied in the endometrium adjacent to the tumor and compared to the nuclear receptor content in the carcinoma. There was a high inverse correlation between the estrogen receptor status and the grade of tumor (R= − 0.45,P= 0.006). The estrogen receptor measured in the endometrium near the tumor showed a negative correlation with the grade of the tumor (R= −0.42,P= 0.013). The estrogen, but not the progesterone, receptor content, was positively related to the age of the patient (P< 0.05). No significant correlation of the receptor status with the depth of myometrial invasion was found, despite the obvious interdependence between the grade and myometrial invasion. The progesterone receptor staining index appeared to be a distinct independent prognostic factor in endometrial cancer. The immunohistochemical analysis of the steroid hormone status in endometrial cancer therefore offers an alternative to the quantitative ligand-binding assay.

scholarly journals Association of genetic polymorphisms of estrogen and progesterone receptors and endometriosis: Meta-analysis

2019 ◽  
Vol 11 (1) ◽  
pp. 25-36
Author(s):  
Priscila Prais Carneiro ◽  
Bruna Vicente de Oliveira ◽  
Antonio Marcio Teodoro Cordeiro Silva
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Estrogen Receptor Alpha ◽  
Meta Analysis ◽  
Estrogen Receptor Beta ◽  
Progesterone Receptors ◽  
Estrogen And Progesterone Receptors ◽  
Receptor Alpha ◽  
Pubmed Database ◽  
Receptor Beta

Purpose: To investigate the association between polymorphisms in the genes of estrogen receptor alpha, estrogen receptor beta, and progesterone receptor and the genesis of endometriosis. Methods: Systematic review and meta-analysis of articles published fully in the PubMed database, in Portuguese, English, or Spanish, from 2006 to 2017, using the descriptors: “endometriosis,” “polymorphism,” “ESR1,” “ESR2,” “PROGINS,” “rs9340799,” “rs4986938,” and “rs1042838.” Results: A total of 20 studies were included based on the criterion of search for susceptibility to endometriosis related to polymorphisms of estrogen receptor alpha, estrogen receptor beta, and progesterone receptor genes. Analysis of all polymorphisms found no association with endometriosis. Conclusion: This meta-analysis showed that estrogen receptor alpha, estrogen receptor beta, and progesterone receptor polymorphisms are not related to susceptibility to endometriosis. However, such results may be able to provide more detailed interpretations of how they influence the pathogenesis of endometriosis.

Estrogen and Progesterone Receptors in Human Colorectal Tumour Cells (Study of 70 Cases)

1988 ◽  
Vol 3 (1) ◽  
pp. 41-48 ◽  
Author(s):  
G. Bracali ◽  
A.M. Caracino ◽  
F. Rossodivita ◽  
C. Bianchi ◽  
M.G. Loli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Estrogen Receptors ◽  
Progesterone Receptors ◽  
Human Colorectal Cancer ◽  
Estrogen And Progesterone Receptors ◽  
Colorectal Tumour ◽  
Estrogen Receptor Positive ◽  
Cytochemical Technique

Estrogen and progesterone receptors were studied in 70 cases of human colorectal cancer by a cytochemical technique. 28.5% of the cases were estrogen-receptor positive and 42.8% progesterone-receptor positive. There was no difference between the sexes for estrogen receptors but the women had more tumours with progesterone receptors than men. The presence of receptors is unrelated to the differentiation of the tumour. More colon tumours were positive than those of the sigma and rectum. The concentration of cells with receptors in positive cancer cases tended to be low or medium-low.

Enzyme-immunoassay for estrogen receptors in human pituitary adenomas

1989 ◽  
Vol 120 (2) ◽  
pp. 233-238 ◽  
Author(s):  
Haruyoshi Nakao ◽  
Masafumi Koga ◽  
Masayo Arao ◽  
Makoto Nakao ◽  
Bunzo Sato ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Enzyme Immunoassay ◽  
Pituitary Adenomas ◽  
Binding Assay ◽  
Estrogen Receptor Status ◽  
Single Point ◽  
Human Pituitary ◽  
Human Pituitary Adenomas ◽  
Estrogen Receptor Positive ◽  
Normal Human

Abstract. We have performed an enzyme-immunoassay for estrogen receptor on 56 human pituitary adenomas and compared the results with a single point estradiol binding assay. There was a significant positive correlation between the two assays of cytoplasmic estrogen receptor (r = 0.960). Normal human pituitaries (N = 2) had an estrogen receptor concentration of 17 fmol/mg protein by enzyme-immunoassay. Of 14 prolactinomas, 6 (43%) contained estrogen receptor with a concentration of 33.5 ± 7.4 (mean ± sem) fmol/mg protein. Six of 11 (55%) macroprolactinomas were estrogen receptorpositive, whereas all 3 microprolactinomas were estrogen receptor-negative. Only one (13%) of 8 GH- and PRL-secreting adenomas, and 3 of 6 (50%) gonadotropin-secreting adenomas were estrogen receptor-positive; the latter had a concentration of 13.5 ± 1.6 fmol/mg protein. Estrogen receptor was not detected in 21 pure GH-secreting adenomas and 7 nonsecreting adenomas. These results demonstrate the precise frequency of estrogen receptor in various human pituitary adenomas, since enzyme-immunoassay as well as single point estradiol binding assay could detect estrogen receptor even in small specimens. Enzyme-immunoassay is suitable for evaluation of estrogen receptor status in human pituitary adenomas.

Progesterone Receptors in Carcinomas of the Upper Aerodigestive Tract

1989 ◽  
Vol 101 (5) ◽  
pp. 527-536 ◽  
Author(s):  
Nicholas J. Berg ◽  
Douglas S. Colvard ◽  
H. Bryan Neel ◽  
Louis H. Weiland ◽  
Thomas C. Spelsberg
Keyword(s):  
Logistic Regression ◽  
Progesterone Receptor ◽  
Human Breast Cancer ◽  
Progesterone Receptors ◽  
Aerodigestive Tract ◽  
Human Breast ◽  
Upper Aerodigestive Tract ◽  
Normal Human ◽  
Steroid Binding ◽  
Disease Grade

This study had three major goals: (1) to vigorously verify the presence of progesterone receptors in squamous cell carcinoma of the upper aerodigestive tract (HN-SCC). Antiprogesterone receptor monoclonal antibodies revealed a distinct band at approximately 120 kilodaltons in samples taken from two of four patients with HN-SCC. These results illustrate that progesterone receptor in HN-SCC has the same molecular weight as progesterone receptor in normal human uterus and human breast cancer. Steroid specificity and saturability results support the evidence that it is true progesterone receptors that are measured and not other receptors or sex steroid-binding globulins; (2) to confirm the biochemical function of progesterone receptors in HN-SCC by assessing the binding of progesterone receptor to acceptor sites on chromosomes in the nucleus; and (3) to establish the clinical significance of progesterone receptor measurement. Patients with positive assays were more likely to be free of disease a mean of 6 months after resection. We used logistic regression to account for site of primary disease, grade of tumor, and stage of disease. This logistic regression was significant with a p = 0.014. Patients with a binding index greater than 2 (19 of 73 patients) were 4.34 times more likely to be free of disease than patients with negative assays.

Sign in / Sign up

Export Citation Format

Share Document